A potentially more effective treatment for HER2 mutant metastatic breast cancer

Researchers have identified a HER2 mutation that confers therapeutic resistance and promotes metastatic behavior in lobular breast cancer. Importantly, they also showed that the drug poziotinib, which is already approved for other cancer types, reduced tumor growth and multi-organ metastasis in laboratory tests and animal models. A phase II clinical trial is on the works to determine the value of this drug in the treatment of patients with this devastating condition.